What do drug monopolies cost consumers in developing countries?

Rebecca Hellerstein

No 530, Staff Reports from Federal Reserve Bank of New York

Abstract: This paper quantifies the effects of drug monopolies and low per-capita income on pharmaceutical prices in developing economies using the example of the antiretroviral drugs (ARVs) used to treat HIV.

Keywords: intellectual property rights; international price discrimination; TRIPS agreement; pharmaceutical industry; markups (search for similar items in EconPapers)
JEL-codes: D4 F13 L1 L65 O34 (search for similar items in EconPapers)
Date: 2011-12-01
New Economics Papers: this item is included in nep-hme
Note: For a published version of this report, see Rebecca Hellerstein, "What Do Drug Monopolies Cost Consumers in Developing Countries?" Economics Letters 116, no. 1 (July 2012): 108-111.
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.newyorkfed.org/medialibrary/media/research/staff_reports/sr530.html (text/html)
https://www.newyorkfed.org/medialibrary/media/research/staff_reports/sr530.pdf (application/pdf)

Related works:
Journal Article: What do drug monopolies cost consumers in developing countries? (2012)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:fip:fednsr:530

Ordering information: This working paper can be ordered from

Access Statistics for this paper

More papers in Staff Reports from Federal Reserve Bank of New York Contact information at EDIRC.
Bibliographic data for series maintained by Gabriella Bucciarelli ().